Actavis CEO Brenton Saunders and Allergan CEO David Pyotton. Pharmaceutical giant Actavis said it would pay US$66 billion for Allergan. Photo: Reuters Actavis CEO Brenton Saunders and Allergan CEO David Pyotton. Pharmaceutical giant Actavis said it would pay US$66 billion for Allergan. Photo: Reuters
Actavis CEO Brenton Saunders and Allergan CEO David Pyotton. Pharmaceutical giant Actavis said it would pay US$66 billion for Allergan. Photo: Reuters

Mega M&A deals point to resurgent corporate optimism

Actavis CEO Brenton Saunders and Allergan CEO David Pyotton. Pharmaceutical giant Actavis said it would pay US$66 billion for Allergan. Photo: Reuters Actavis CEO Brenton Saunders and Allergan CEO David Pyotton. Pharmaceutical giant Actavis said it would pay US$66 billion for Allergan. Photo: Reuters
Actavis CEO Brenton Saunders and Allergan CEO David Pyotton. Pharmaceutical giant Actavis said it would pay US$66 billion for Allergan. Photo: Reuters
READ FULL ARTICLE